Scarica l'app Stockscreener
8.41
10.51%
0.80
Dopo l'orario di chiusura:
8.43
0.02
+0.24%
Precedente Chiudi:
$7.61
Aprire:
$7.7
Volume 24 ore:
3.18M
Relative Volume:
2.20
Capitalizzazione di mercato:
$694.44M
Reddito:
-
Utile/perdita netta:
$-314.85M
Rapporto P/E:
-2.3475
EPS:
-3.5825
Flusso di cassa netto:
$-283.27M
1 W Prestazione:
+11.54%
1M Prestazione:
+17.46%
6M Prestazione:
+80.86%
1 anno Prestazione:
-2.44%
Intervallo 1D:
$7.675
$8.43
Intervallo di 1 settimana:
$7.05
$8.43
Portata 52W:
$2.68
$13.24
Replimune Group Inc Stock (REPL) Company Profile
Nome
Replimune Group Inc
Settore
Industria
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
8.41 | 694.44M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-09-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-06-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-04-17 | Ripresa | Piper Sandler | Overweight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-17 | Iniziato | BTIG Research | Buy |
| 2020-11-02 | Iniziato | Jefferies | Buy |
| 2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-09-04 | Iniziato | ROTH Capital | Buy |
| 2019-07-23 | Iniziato | Chardan Capital Markets | Buy |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-25 | Iniziato | Wedbush | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Iniziato | JP Morgan | Overweight |
| 2018-08-14 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Replimune Group Inc Borsa (REPL) Ultime notizie
Replimune Group Inc. Faces Mixed Market Reactions Amid Financial Updates - timothysykes.com
Replimune Group Inc. Stock Dips Amid Financial Challenges and Market Pressures - timothysykes.com
REPL PE Ratio & Valuation, Is REPL Overvalued - Intellectia AI
Replimune, Grace among biotechs with April PDUFA dates - biocentury.com
REPL files Form 144 notice (NASDAQ: REPL) with RSU vesting details - Stock Titan
Replimune Group Inc (7R8.SG) stock price, news, quote and history - Yahoo Finance Singapore
Replimune Group (NASDAQ:REPL) Shares Up 7.2%Should You Buy? - MarketBeat
Replimune Shares Approach a Pivotal Regulatory Verdict - AD HOC NEWS
Meme Stocks: Can Replimune Group Inc expand its profit margins2026 Snapshot & AI Driven Price Predictions - baoquankhu1.vn
Entry Recap: Is Replimune Group Inc stock undervalued right now2026 Price Targets & Verified Swing Trading Watchlists - baoquankhu1.vn
Replimune Group (FRA:7R8) PB Ratio : 2.79 (As of Mar. 28, 2026) - GuruFocus
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know - MSN
Aug Update: Is now the right time to enter Replimune Group Inc2026 Price Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Analyst Upgrade: Is IBTA affected by consumer sentiment2026 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
REPL Technical Analysis | Trend, Signals & Chart Patterns | REPLIMUNE GROUP INC (NASDAQ:REPL) - chartmill.com
Replimune's Oncolytic Viral Therapy For Melanoma Faces Second Shot At FDA Approval - RTTNews
Replimune Shares Skyrocket After FDA Accepts Resubmitted BLA for Melanoma Therapy - MSN
Aug PostEarnings: Does Replimune Group Inc align with a passive investing strategyWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Does Replimune Group (REPL) have the potential to rally 79.61% as Wall Street analysts expect? - MSN
Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL - MarketBeat
Institutional Investors Double Down on Replimune Amid Market Turmoil () - aktiencheck.de
Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat
Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat
Quinn Opportunity Partners LLC Invests $2.73 Million in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Down 8%Here's What Happened - MarketBeat
Wedbush Upgrades Replimune Group (REPL) - MSN
REPL: Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress - TradingView
Replimune Group (NASDAQ:REPL) Trading 11.1% HigherHere's Why - MarketBeat
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - Finviz
Replimune Stock Quote, Share Price, News and Analysis - Longbridge
REPL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions? - Bitget
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? - Finviz
Replimune to Present at Two Upcoming Investor Conferences - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Hold" by Analysts - MarketBeat
Erste Asset Management GmbH Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group, Inc. (REPL) Stock Analysis: A High-Potential Biotech Play with 67% Upside - DirectorsTalk Interviews
Replimune Group Stock Price Forecast. Should You Buy REPL? - StockInvest.us
Replimune's Pivotal FDA Verdict Approaches - AD HOC NEWS
Market Leaders: Can Replimune Group Inc expand its profit margins2025 Fundamental Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Analyst Calls: Is Apyx Medical Corporation in accumulation or distribution phaseEarnings Miss & Real-Time Volume Analysis - baoquankhu1.vn
Replimune Shares Approach a Pivotal Regulatory Milestone - AD HOC NEWS
Replimune Group, Inc. (REPL) Stock Analysis: Unpacking a 50% Potential Upside in Biotechnology - DirectorsTalk Interviews
Replimune: Multiple Shots On Goal But A High Risk Binary Approaches - Seeking Alpha
What is Replimune Group Inc.’s market positionQuarterly Profit Summary & Precise Swing Trade Entry Alerts - mfd.ru
Replimune Group (REPL) director gifts 25,000 common shares - Stock Titan
Institutional Confidence Surges in Replimune as Key Drug Review Looms - AD HOC NEWS
Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP - MarketBeat
Replimune rebounds despite analyst downgrades on FDA rejection - MSN
Forbion discloses 3.5% Replimune (REPL) stake in ownership filing - Stock Titan
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):